초록 ▼

The production of a thrombin preparation which is obtained from prothrombin which is, after activation to thrombin without the addition of thromboplastin, purified by a hydrophobic interaction chromatography, it being possible subsequently also to inactivate or remove viruses, is described. Before

The production of a thrombin preparation which is obtained from prothrombin which is, after activation to thrombin without the addition of thromboplastin, purified by a hydrophobic interaction chromatography, it being possible subsequently also to inactivate or remove viruses, is described. Before or after the hydrophobic interaction chromatography it is also possible in addition to carry out a cation exchange chromatography. A thrombin preparation which contains as stabilizer a noncovalently binding inhibitor and to which further stabilizers can be added for stabilization in the liquid state is additionally described.

대표청구항 ▼

We claim: 1. A stable thrombin preparation comprising thrombin and benzamidine or p-aminobenzamidine as stabilizer, and further comprising calcium chloride sodium chloride as stabilizer, at least one buffer substance, and at least one of I-histidine, mannitol, sodium succinate, sodium lactate, or I

We claim: 1. A stable thrombin preparation comprising thrombin and benzamidine or p-aminobenzamidine as stabilizer, and further comprising calcium chloride sodium chloride as stabilizer, at least one buffer substance, and at least one of I-histidine, mannitol, sodium succinate, sodium lactate, or I-arginine wherein, after at least 12 months of storage at 20-25�� C. in the liquid state, the thrombin activity of the preparation, measured by a coagulation test with a fibrinogen substrate, over 70-80% of its initial level prior to the storage. 2. The preparation of claim 1, wherein the pH of the preparation is from 5.0 to 8.0. 3. The preparation of claim 1, comprising mannitol at a concentration of 1-2% (w/v). 4. The preparation of claim 1, wherein the at least one of, I-histidine, mannitol, sodium succinate, sodium lactate, or I-arginine does not increase the viscosity of the preparation. 5. The preparation of claim 1, wherein the preparation comprises a hemostatic or a constituent of a hemostatic. 6. The preparation of claim 1, wherein the preparation comprises a constituent of a tissue glue.